Advertisement

Primary Central Nervous System Lymphomas

  • Natsuo OyaEmail author
Chapter

Abstract

Radiotherapy (RT) after systemic chemotherapy including high-dose (HD) methotrexate is widely accepted as the standard treatment for primary central nervous system lymphoma (PCNSL). Treatment must consider the blood brain barrier as it characterizes the clinical behavior of PCNSL. For consolidation RT in patients with complete remission (CR) after chemotherapy, 23.4–30 Gy of whole-brain radiotherapy (WBRT) is recommended. For salvage RT in patients with non-CR or recurrent disease (RD) after chemotherapy, 36–45 Gy of WBRT or 30 Gy of WBRT followed by 10–20 Gy of boost irradiation is recommended. The reported 5-year survival rate of PCNSL patients is 30–50%; it is worse than for patients with other extranodal lymphomas. Late neurological toxicity is a major problem in long survivors after HD methotrexate and WBRT. Chemotherapy alone may be considered in elderly PCNSL patients who are at high risk for radiation-induced neurocognitive dysfunction.

Keywords

Central nervous system lymphoma (PCNSL) Whole-brain radiotherapy (WBRT) Intraocular lymphoma High-dose methotrexate Neurocognitive dysfunction 

References

  1. 1.
    Reni M, Ferreri AJ, Guha-Thakurta N, et al. Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose MTX. Int J Radiat Oncol Biol Phys. 2001;51:419–25.CrossRefPubMedGoogle Scholar
  2. 2.
    Shibamoto Y, Sumi M, Onodera S, et al. Primary CNS lymphoma treated with radiotherapy in Japan: a survey of patients treated in 2005-2009 and a comparison with those treated in 1985-2004. Int J Clin Oncol. 2014;19:963–71.CrossRefPubMedGoogle Scholar
  3. 3.
    Lai R, Rosenblum MK, DeAngelis LM. Primary CNS lymphoma: a whole-brain disease? Neurology. 2002;59:1557–62.CrossRefPubMedGoogle Scholar
  4. 4.
    Yahalom J, Illidge T, Specht L, et al. International Lymphoma Radiation Oncology Group. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92:11–31.Google Scholar
  5. 5.
    Hong JT, Chae JB, Lee JY, Kim JG, Yoon YH. Ocular involvement in patients with primary CNS lymphoma. J Neurooncol. 2011;102:139–45.CrossRefPubMedGoogle Scholar
  6. 6.
    Liu BL, Cheng JX, Zhang X, Zhang W, Cheng H. Limited role of surgery in the management of primary central nervous system lymphoma. Oncol Rep. 2009;22:439–49.PubMedGoogle Scholar
  7. 7.
    Shibamoto Y, Sasai K, Oya N, et al. Systemic chemotherapy with vincristine, cyclophosphamide, doxorubicin and prednisolone following radiotherapy for primary central nervous system lymphoma: a phase II study. J Neurooncol. 1999;42:161–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Mead GM, Bleehen NM, Gregor A, et al. A Medical Research Council randomized trial in patients with primary cerebral non-Hodgkin lymphoma. Cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer. 2000;89:1359–70.CrossRefPubMedGoogle Scholar
  9. 9.
    Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25:4730–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31:3971–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Omuro AM, Taillandier L, Chinot O, et al. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol. 2007;85:207–11.CrossRefPubMedGoogle Scholar
  12. 12.
    Pels H, Juergens A, Glasmacher A, et al. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. J Neurooncol. 2009;91:299–305.CrossRefPubMedGoogle Scholar
  13. 13.
    Pels H, Schmidt-Wolf IG, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21:4489–95.CrossRefPubMedGoogle Scholar
  14. 14.
    Correa DD, Shi W, Abrey LE, et al. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro Oncol. 2012;14:101–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Herrlinger U, Kuker W, Uhl M, et al. NOA-03 trial of highdose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol. 2005;57:843–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Milgrom SA, Yahalom J. The role of radiation therapy in the management of primary central nervous system lymphoma. Leuk Lymphoma. 2015;56:1197–204.CrossRefPubMedGoogle Scholar
  17. 17.
    Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006;24:4570–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Batchelor T, Carson K, O’Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003;21:1044–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–22.CrossRefPubMedGoogle Scholar
  20. 20.
    Ferreri AJ, Reni M. Prognostic factors in primary central nervous system lymphomas. Hematol Oncol Clin North Am. 2005;19:629–49.CrossRefPubMedGoogle Scholar
  21. 21.
    Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11:1036–47.CrossRefPubMedGoogle Scholar
  22. 22.
    Zacher J, Kasenda B, Engert A, et al. The role of additional radiotherapy for primary central nervous system lymphoma. Cochrane Database Syst Rev. 2011. www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD009211/frame.html.
  23. 23.
    Kasenda B, Ferreri AJ, Marturano E, et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL). A systematic review and individual patient data meta-analysis. Ann Oncol. 2015;26:1305–13.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Doolittle ND, Korfel A, Lubow MA, et al. Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology. 2013;81:84–92.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Zhu JJ, Gerstner ER, Engler DA, et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol. 2009;11:211–5.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Iwabuchi M, Shibamoto Y, Sugie C, Ayakawa S, Ogino H, Baba F. Partial-brain radiotherapy for primary central nervous system lymphoma: multi-institutional experience. J Radiat Res. 2016;57(2):164–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Teckie S, Yahalom J. Primary intraocular lymphoma: treatment outcomes with ocular radiation therapy alone. Leuk Lymphoma. 2014;55:795–801.CrossRefPubMedGoogle Scholar
  28. 28.
    Fisher B, Seiferheld W, Schultz C, DeAngelis L, Nelson D, Schold SC, Curran W, Mehta M. Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma. J Neurooncol. 2005;74:201–5.CrossRefPubMedGoogle Scholar
  29. 29.
    Shibamoto Y, Hayabuchi N, Hiratsuka J, et al. Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation. Cancer. 2003;97:128–33.CrossRefPubMedGoogle Scholar
  30. 30.
    Shibamoto Y, Sumi M, Takemoto M, et al. Analysis of radiotherapy in 1054 patients with primary central nervous system lymphoma treated from 1985 to 2009. Clin Oncol. 2014;26:653–60.CrossRefGoogle Scholar
  31. 31.
    DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group study 93-10. J Clin Oncol. 2002;20:4643–8.CrossRefPubMedGoogle Scholar
  32. 32.
    O’Brien PC, Roos DE, Pratt G, et al. Combined-modality therapy for primary central nervous system lymphoma: long-term data from a phase II multicenter study (Trans Tasman Radiation Oncology Group). Int J Radiat Oncol Biol Phys. 2006;64:408–13.CrossRefPubMedGoogle Scholar
  33. 33.
    Kim BH, Kim IH, Park SH, Park CK, Jung HW, Kim TM, Lee SH, Heo DS. Low-dose whole brain radiotherapy with tumor bed boost after methotrexate-based chemotherapy for primary central nervous system lymphoma. Cancer Res Treat. 2014;46:261–9.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, DeAngelis LM. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24:5711–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Durkin SR, Roos D, Higgs B, Casson RJ, Selva D. Ophthalmic and adnexal complications of radiotherapy. Acta Ophthalmol Scand. 2007;85:240–50.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2017

Authors and Affiliations

  1. 1.Department of Radiation Oncology, Faculty of Life SciencesKumamoto UniversityKumamotoJapan

Personalised recommendations